Evidence map›Paper›PMID 30670791›Full record

ArticleCancer gene therapy2019

Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma.

V Konduri, M M Halpert, Y C Baig, R Coronado, J R Rodgers, J M Levitt, B Cerroni, S Piscoya, N Wilson, L DiBernardi and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. SonicatedCurrent issues in molecular biology · 2022
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

V Konduri *Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
M M Halpert *Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
Y C BaigDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
R CoronadoLester Smith Medical Research Institute, San Antonio, TX, 78229, USA.
J R RodgersDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
J M LevittDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.
B CerroniGulf Coast Veterinary Specialists, Houston, TX, 77027, USA.
S PiscoyaGulf Coast Veterinary Specialists, Houston, TX, 77027, USA.
N WilsonGulf Coast Veterinary Specialists, Houston, TX, 77027, USA.
L DiBernardiGulf Coast Veterinary Specialists, Houston, TX, 77027, USA.
Z OmarbekovSunset Boulevard Animal Clinic, Houston, TX, 77005, USA.
L SeelhoffSunset Boulevard Animal Clinic, Houston, TX, 77005, USA.
V RaviDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
L Douglass *Sunset Boulevard Animal Clinic, Houston, TX, 77005, USA.
W K Decker *Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 77030, USA. decker@bcm.edu.
Baylor College of Medicine · USSunset Laboratory (United States) · USLester Smith Medical Research Institute · USThe University of Texas MD Anderson Cancer Center · US

Funding

Regulation of Innate Dendritic Cell CTLA-4R01AI127387 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI WILLIAM Karl DECKER · 2017 to 2026
$3.9M
NIAID NIH HHS R01 AI127387
6 · The paper itself

Abstract

Angiosarcoma is a deadly neoplasm of the vascular endothelium. Metastatic disease is often present at diagnosis, and 5-year survival is only 10-35%. Although there exist no immunocompetent mouse models of angiosarcoma with which to study immune-based approaches to therapy, angiosarcoma is a major killer of companion dogs, responsible for up to 2% of all canine deaths in some susceptible breeds or an estimated 120,000 per year in the US. The canine disease (HSA) often presents in the spleen as acute hemoabdomen secondary to splenic rupture. Even if life-saving splenectomy is performed, median overall survival (OS) is only 48 days, and 1-year survival is negligible. Here we report the analysis of a pilot phase I open-label trial of chemo-immunotherapy performed on consecutively presenting splenectomized canines with histologically verified HSA. Subjects received an abbreviated course of low-dose doxorubicin plus alpha interferon and an autologous dendritic cell-therapy reported to enhance durable CD8

Indexed as

AnimalsCancer VaccinesCells, CulturedCombined Modality TherapyDendritic CellsDisease Models, AnimalDog DiseasesDogsDoxorubicinFemaleHemangiosarcomaImmunophenotypingImmunotherapyMaleMonte Carlo MethodVaccinationCancer VaccinesDoxorubicin

Identifiers

PMID30670791
PMCPMC6760631
OpenAlexW2914886863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.